IPSC vs. SOPH, GOSS, ANNX, HURA, DBVT, PRME, NGNE, GNFT, ELDN, and VYGR
Should you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include SOPHiA GENETICS (SOPH), Gossamer Bio (GOSS), Annexon (ANNX), TuHURA Biosciences (HURA), DBV Technologies (DBVT), Prime Medicine (PRME), Neurogene (NGNE), Genfit (GNFT), Eledon Pharmaceuticals (ELDN), and Voyager Therapeutics (VYGR). These companies are all part of the "pharmaceutical products" industry.
Century Therapeutics vs.
Century Therapeutics (NASDAQ:IPSC) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment, community ranking and earnings.
Century Therapeutics received 23 more outperform votes than SOPHiA GENETICS when rated by MarketBeat users. However, 70.37% of users gave SOPHiA GENETICS an outperform vote while only 70.00% of users gave Century Therapeutics an outperform vote.
SOPHiA GENETICS has higher revenue and earnings than Century Therapeutics. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.
SOPHiA GENETICS has a net margin of -110.71% compared to Century Therapeutics' net margin of -4,837.73%. SOPHiA GENETICS's return on equity of -55.06% beat Century Therapeutics' return on equity.
In the previous week, SOPHiA GENETICS had 1 more articles in the media than Century Therapeutics. MarketBeat recorded 5 mentions for SOPHiA GENETICS and 4 mentions for Century Therapeutics. SOPHiA GENETICS's average media sentiment score of 0.46 beat Century Therapeutics' score of 0.39 indicating that SOPHiA GENETICS is being referred to more favorably in the news media.
50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 6.8% of Century Therapeutics shares are owned by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Century Therapeutics has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500.
Century Therapeutics currently has a consensus target price of $4.40, suggesting a potential upside of 692.22%. SOPHiA GENETICS has a consensus target price of $6.80, suggesting a potential upside of 125.17%. Given Century Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Century Therapeutics is more favorable than SOPHiA GENETICS.
Summary
Century Therapeutics beats SOPHiA GENETICS on 10 of the 18 factors compared between the two stocks.
Get Century Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Century Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:IPSC) was last updated on 5/2/2025 by MarketBeat.com Staff
Buy IPSC Stock Free IPSC Stock Alerts